What Kinexus Corporation does

Kinexus Bioinformatics Corporation, founded in 1999 in Vancouver, British Columbia, is a private, founder-led proteomics services company specializing in cell signaling protein profiling for biomedical researchers. The company operates an integrated discovery platform anchored by antibody microarray technology (the Kinex KAM-2025 array carrying 2,027 antibodies across 949 unique signaling proteins), custom macroarrays (peptide, antibody, lysate), in silico kinase substrate prediction algorithms (IKSP, IKMP, IPMP), in vitro kinase/phosphatase substrate profiling (SPIMA), kinase inhibitor specificity screening (KIDMAS), multi-immunoblotting validation services (Kinetworks KCPS 1.0 and KCSS 1.0), mass spectrometry protein identification (PIMS), custom peptide synthesis (CSPP, CPAP SPOT arrays), and custom rabbit polyclonal antibody production (CAP). Underlying the platform are proprietary bioinformatics algorithms co-developed with the University of British Columbia and Simon Fraser University, and a large in-house catalog of more than 1,600 validated antibodies and 1,600+ stock synthetic peptides.

Kinexus generates revenue through three primary streams: (1) fee-for-service proteomics and bioinformatics work delivered through a mail-in/courier model in which clients send cell or tissue lysates to the Vancouver facility with a typical 3-4 week turnaround; (2) standalone product sales of antibodies (typically US$99 per 25 µg) and peptides via a Shopify e-commerce storefront; and (3) unit-priced in silico bioinformatics reports (IKSP at US$399 per kinase, IKMP at US$99 per analysis, IPMP on quote) and ancillary services such as custom graphics (US$99 per slide) and KiNetscape custom pathway mapping (from US$400). Customers are distributed globally across academic research institutions and biopharmaceutical companies in over 40 countries, with over 3,500 lifetime clients served and more than 10,000 cumulative proteomics screens performed over the company's 26-year operating history.

The company maintains and distributes open-access cell-signaling reference data through its SigNET KnowledgeBank — covering PhosphoNET (950,000+ phosphorylation sites), KinaseNET (530+ kinases), KiNECTOR (22,000+ kinase-substrate relationships), DrugKiNET (800+ compounds, 105,000+ experiments), and KiNET-AM (1.5 million+ measurements from nearly 2,000 microarray analyses) — which functions simultaneously as an educational funnel, a thought-leadership asset, and a competitive differentiator. Kinexus has remained privately held and founder-operated throughout its history, with no disclosed institutional funding, M&A activity, or recapitalization events.

Name

Kinexus Corporation

Legal name

Kinexus Bioinformatics Corporation

Website

https://kinexus.ca

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Kinexus Corporation is a private Vancouver-based proteomics services company founded in 1999 that provides antibody microarray, immunoblotting, in silico kinase prediction, and custom antibody/peptide services to academic and biopharmaceutical researchers in over 40 countries.

Ownership category

akta.pro rank

Product category

Proteomics Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Proteomics & Biomarker Analytical Testing (HLAGADAG), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Proteomics services
• Antibody microarrays
• Kinase profiling
• Phosphoproteomics research
• Custom peptide synthesis

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Proteomics Services: Core revenue from providing antibody microarray services (KAM-2025), immunoblotting services (Kinetworks™ KCPS 1.0 and KCSS 1.0), kinase/phosphatase substrate profiling (SPIMA), kinase inhibitor profiling (KIDMAS), mass spectrometry protein identification (PIMS), custom peptide and antibody production, and custom graphics services. Turnaround time is typically 3-4 weeks.
2. Standalone Products (Antibodies and Peptides): Sale of over 1,600 validated rabbit polyclonal antibodies and over 1,600 stock synthetic peptides as standalone products through their Shopify e-commerce platform. Antibodies typically priced at US$99 per 25 µg.
3. In Silico Bioinformatics Services: IKSP (In Silico Kinase Substrate Specificity Prediction) at US$399 per kinase, IKMP (In Silico Kinase Match Prediction) at US$99 per analysis, and IPMP (In Silico Phosphoprotein Match Prediction) services for phosphosite and kinase prediction.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Kinexus Corporation provides integrated proteomics services and products for biomedical researchers, centered on its proprietary Kinex™ KAM-2025 antibody microarray platform that profiles cell signaling proteins across 949 unique targets. The company delivers custom antibody and peptide synthesis, multi-immunoblotting validation (Kinetworks™), kinase/phosphatase substrate profiling (SPIMA, KIDMAS), in silico kinase substrate prediction, mass spectrometry protein identification, and maintains open-access SigNET knowledgebases covering millions of phosphorylation sites and kinase relationships.

Product overview

Kinexus offers an integrated proteomics and bioinformatics services platform centered on antibody microarray technology (Kinex™ KAM-2025) and kinase/phosphatase research. The platform comprises: (1) high-content antibody microarrays and custom macroarrays (peptide, antibody, lysate); (2) in silico kinase substrate prediction services (IKSP, IKMP, IPMP) and in vitro kinase/phosphatase substrate profiling (SPIMA); (3) custom synthesis services for peptides (CSPP, CPAP SPOT arrays) and antibodies (CAP); (4) immunoblotting validation services (Kinetworks™ KCPS, KCSS); (5) mass spectrometry protein identification (PIMS); and (6) open-access knowledgebases (PhosphoNET, KinaseNET, KiNECTOR, DrugKiNET, KiNET-AM) containing millions of data points on human phosphorylation sites, protein kinases, kinase-substrate relationships, and kinase-drug interactions. These services are designed to work together as a unified discovery pipeline from initial biomarker screening through validation.

Differentiator

Problem solved

Functional benefit

Brands

• Kinex™: Antibody microarray platform including KAM-2025 product line
• Kinetworks™
• SigNET KnowledgeBank
• KiNET-AM
• CSPP
• CPAP
• SPIMA
• KIDMAS
• PIMS

Products and services

• Kinex™ KAM-2025 Antibody Microarray High-content antibody microarray featuring 2,027 pan- and phosphosite-specific antibodies for tracking approximately 949 unique signaling proteins including protein kinases, phosphatases, and other cell signaling proteins particularly important in oncology, neurology, and diabetes research.
• Kinetworks™ KCPS 1.0 Multi-Antibody Western Blotting Multi-antibody immunoblotting service evaluating up to 18 different antibodies against proteins in a single tissue or cell lysate sample for validation of microarray results.
• Kinetworks™ KCSS 1.0 Multi-Sample Western Blotting Multi-sample immunoblotting service tracking a protein target across up to 14 different cell or tissue specimens on a single Western blot for dose responses, time courses, or biological reproducibility.
• CAP Custom Antibody Production Custom production of affinity-purified rabbit polyclonal antibodies against signaling proteins including peptide synthesis, rabbit immunizations, and peptide affinity purification, starting at US$1,299.
• CSPP Custom Synthetic Peptide Production Synthesis of high-quality soluble peptides including phosphopeptides, cyclic peptides, and custom-labeled peptides (FITC, biotin, etc.) for kinase substrates, pseudo-substrate inhibitors, and immunogenic peptides.
• CPAP Custom SPOT Peptide Arrays Peptide synthesis directly on cellulose membranes using SPOT technology for high-density arrays, supporting epitope mapping, substitution analysis, truncation analysis, and random/combinatorial/phosphopeptide library screening.
• SPIMA Kinase/Phosphatase Substrate Profiling In vitro service using KAM-2025 antibody microarray to identify physiological substrates for over 360 recombinant human protein kinases and 40 protein phosphatases in cell and tissue lysates.
• KIDMAS Kinase-Inhibitor Profiling Kinase Inhibitor Displacement Microarray-based Screen service that determines specificity of kinase inhibitors by detecting competitive binding at active sites using FSBA probe technology across at least 364 captured human protein kinases.
• IKSP In Silico Kinase Substrate Specificity Prediction Bioinformatics service using proprietary algorithms to predict specificity of nearly 500 human protein kinases based on catalytic domain sequences and known substrate phosphosite pairs, priced at US$399 per kinase.
• IKMP In Silico Kinase Substrate Match Prediction Bioinformatics service to identify optimal kinases for a given phosphorylation site sequence, testing any known or putative phosphosite against scoring matrices for nearly 500 human protein kinases, priced at US$99 per analysis.
• IPMP In Silico Phosphoprotein Match Prediction Comprehensive bioinformatics service identifying putative phosphosites in human proteins and predicting kinases likely to phosphorylate these sites across approximately 500 kinases, with evolutionary conservation analysis.
• KCPM Custom Peptide Macroarray Custom peptide macroarrays with robotically spotted peptides on cellulose or nitrocellulose membranes or glass slides for epitope mapping, kinase and phosphatase substrate specificity, and protein-protein interaction studies.
• KCAM Custom Antibody Macroarray Custom antibody macroarrays with robotically spotted antibodies on membranes or glass slides for detection of proteins in bodily fluids and tissue lysates.
• KRLM Custom Lysate Macroarray Custom arrays of robotically spotted tissue and cell lysates or biofluid specimens for biomarker validation across large sample cohorts.
• PIMS Protein Identification by Mass Spectrometry Protein fingerprinting service using LC-MS/MS mass spectrometry to identify cross-immunoreactive proteins detected in Kinetworks or SPIMA analyses.
• Custom Graphics Services Production of publication and presentation-ready figures including colored slides, bar graphs, and signaling pathway diagrams from Kinetworks and Kinex microarray results, at US$99 per slide.
• Kinexus Validated Antibodies and Peptides Catalog Online catalog of over 1,600 in-house developed pan- and phosphosite-specific antibodies and over 1,600 stock synthetic peptides sold as standalone reagents via Shopify, typically priced at US$99 per 25 µg of antibody.

Quantifiable outcome

• Over 3,500 clients served in over 40 countries since 1999
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• University of British Columbia (UBC)coreStrategic or Co-development PartnerAcademic partnership with UBC's Departments of Mathematics and Computer Science and the MITACS Group for development of proprietary kinase substrate prediction algorithms using mutual information and amino acid interaction scoring. Collaboration resulted in 'cracking the kinase code' to predict kinase specificity from catalytic domain amino acid sequences.
• Simon Fraser University (SFU)coreStrategic or Co-development PartnerAcademic partnership for development of proprietary kinase substrate prediction algorithms. Collaboration with UBC and SFU mathematics and computer science departments created algorithms for predicting specificity of nearly 500 human protein kinases.

Scale indicators15 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Abcam: Abcam is a major antibody reagent supplier (now part of Danaher) with a catalog covering thousands of targets including phosphorylation-specific antibodies. Overlaps with Kinexus on validated rabbit polyclonal antibodies and recombinant antibody reagents for cell signaling research.
• RayBiotech: RayBiotech is a direct competitor in antibody microarray and multiplex immunoassay services for biomarker discovery, with overlapping technology (antibody arrays) and customer base (academic and translational researchers).
• Cell Signaling Technology (CST): CST is the dominant commercial supplier of phospho-specific and signaling antibodies, offering antibody-based proteomics tools and validation services. Direct overlap with Kinexus in antibody reagents for cell signaling and kinase research, particularly for academic and pharma discovery customers.
• PhosphoSolutions: PhosphoSolutions is a small specialty vendor focused exclusively on phospho-specific antibodies for neuroscience and signaling research. Direct niche competitor with similar technology foundation and customer profile.
• Full Moon BioSystems: Full Moon BioSystems produces antibody arrays and phosphorylation assays that directly overlap with Kinexus's KAM antibody microarray platform and target the same academic and biomarker discovery customers.

Emerging players

• Olink Holding: Olink's Proximity Extension Assay (PEA) technology is an emerging next-generation proteomics platform competing for the same biomarker discovery budgets that fund Kinexus antibody microarrays, particularly in pharma translational research.
• Active Motif: Active Motif provides antibodies, kits, and services for epigenetics, chromatin, and cell signaling research. Comparable as a specialty proteomics tools provider with overlapping antibody catalog and service offerings for translational researchers.

Broad incumbents

• Promega Corporation: Promega is a broad life science tools incumbent offering antibodies, peptides, mass spectrometry reagents, and custom protein production services that overlap with several Kinexus service lines (CAP, CSPP, PIMS).
• Bio-Techne: Bio-Techne is a diversified life science tools incumbent offering antibodies, proteins, ELISA kits, and proteomics platforms (including Simple Western). Comparable as a broad-spectrum protein research tools provider serving similar academic and pharma customers.
• Standard BioTools (formerly Fluidigm / SomaLogic): Standard BioTools acquired SomaLogic and operates the SOMAscan aptamer-based proteomics platform, a high-multiplex competitor targeting similar biomarker discovery and translational proteomics applications as Kinexus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC_GL-BCsGRrnKiQ_6qV1jeA
• Xx.com/kinexus1
• Facebookfacebook.com/270671866291412
• LinkedInlinkedin.com/company/kinexus

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinexus Corporation